Is Adoptive Cellular Therapy With Non-T-Cell Immune Effectors the Future?
Cancer J
; 27(2): 168-175, 2021.
Article
in En
| MEDLINE
| ID: mdl-33750077
ABSTRACT
ABSTRACT Success from checkpoint blockade and adoptive cell therapy has brought a new hope in cancer immunotherapy. Adoptive cell therapy involves the isolation of immune cells, ex vivo activation and/or expansion, and reinfusion into the patients, and their effect can be dramatically increased by the incorporation of chimeric antigen receptors specific to molecules expressed on tumor cells. Chimeric antigen receptor T cells have shown exciting results in the treatment of liquid malignancies; nevertheless, they suffer from limitations including severe adverse effects such as cytokine release syndrome and neurotoxicity seen in patients as well as a potential for causing graft-versus-host disease in an allogeneic setting. It is thus imperial to explore innate immune cells including natural killer cells, macrophages, natural killer T cells, and γδ T cells. Here, we provide a broad overview of the major innate immune cells and their potential for adoptive cell therapy and chimeric antigen receptor engineering.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunotherapy, Adoptive
/
Receptors, Chimeric Antigen
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer J
Journal subject:
NEOPLASIAS
Year:
2021
Document type:
Article
Affiliation country: